<?xml version="1.0" encoding="UTF-8"?>
<p>Regular administration of biologics, such as anti-IL-5, anti-IL-4 and anti-IgE antibodies, has become a common treatment option for severe asthma as well as for uncontrolled cases of CU and AD. It is critical to control disease activity through the prevention of exacerbations.
 <xref rid="B45" ref-type="bibr">45</xref> In addition, there have been no studies showing that biological agents may induce immune suppression and increase the risk of COVID-19. For these reasons, there is no need to stop or reduce the dosage of biologics scheduled.
 <xref rid="B29" ref-type="bibr">29</xref> However, most of the biologics require periodic parenteral/subcutaneous administration, for which such patients have to visit an allergy clinic to receive medications according to a treatment protocol. In these patients, it is advisable to provide required protective equipment to both HCWs and patients and to administer the medication with minimal contact.
 <xref rid="B9" ref-type="bibr">9</xref>
 <xref rid="B10" ref-type="bibr">10</xref>
</p>
